{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:24:15Z","timestamp":1793363055616,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.breast.2026.104903","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:26:43Z","timestamp":1787034403000},"page":"104903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Biomarker-based risk stratification for predicting late recurrence and benefit of extended endocrine therapy: A secondary analysis of the IDEAL trial"],"prefix":"10.1016","volume":"89","author":[{"given":"Tejal.D.","family":"Durgekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0023-7353","authenticated-orcid":false,"given":"Shyamili","family":"Goutham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elma.Meershoek-Klein","family":"Kranenbarg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badada.Ananthamurthy","family":"Savitha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.S.","family":"Deepti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Krishnamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hein","family":"Putter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manvi","family":"Sunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik J.","family":"Blok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis.J.H.","family":"van de Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter.J.K.","family":"Kuppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1160-8102","authenticated-orcid":false,"given":"Manjiri","family":"Bakre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104903_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164190","article-title":"Extended adjuvant endocrine therapy in early breast cancer patients-review and perspectives","volume":"15","author":"Bekes","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2026.104903_bib3","article-title":"NCCN guidelines version 2.2025","author":"Rashmi Kumar","year":"2025","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2026.104903_bib4","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Abe","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104903_bib5","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104903_bib6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104903_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.18_suppl.5","article-title":"aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer","volume":"31","author":"Gray","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104903_bib8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.6004\/jnccn.2014.0058","article-title":"Breast Cancer Version 3.2014","volume":"12","author":"Gradishar","year":"2014","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.breast.2026.104903_bib9","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1200\/JCO.2013.54.2258","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update","volume":"32","author":"Burstein","year":"2014","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.breast.2026.104903_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10549-007-9698-1","article-title":"Letrozole in the extended adjuvant setting: MA.17","volume":"105","author":"Goss","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104903_bib11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(18)30621-1","article-title":"A randomized trial of five years of letrozole versus placebo after aromatase inhibitor-based therapy: NRG Oncology\/NSABP B-42","volume":"20","author":"Mamounas","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104903_bib12","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S1470-2045(17)30600-9","article-title":"Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial","volume":"18","author":"Tjan-Heijnen","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104903_bib13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2104162","article-title":"Duration of adjuvant aromatase-inhibitor therapy in Postmenopausal Breast cancer","volume":"385","author":"Gnant","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104903_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/jnci\/djx134","article-title":"Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05)","volume":"110","author":"Blok","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2026.104903_bib15","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-017-0986-2","article-title":"Extended adjuvant endocrine therapy in early breast cancer: a meta-analysis of published randomized trials","volume":"34","author":"Ibrahim","year":"2017","journal-title":"Med Oncol"},{"key":"10.1016\/j.breast.2026.104903_bib16","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s12282-020-01196-8","article-title":"Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis","volume":"28","author":"Chen","year":"2021","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2026.104903_bib17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0140-6736(25)01013-X","article-title":"Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy","volume":"406","author":"Braybrooke","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104903_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113604","article-title":"Extended adjuvant endocrine treatment in luminal breast cancers in the era of genomic tests","volume":"23","author":"Saponaro","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.breast.2026.104903_bib19","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdz298","article-title":"Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis","volume":"30","author":"Ferreira","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104903_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105057","article-title":"Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance","volume":"10","author":"Lobo-Martins","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104903_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25115717","article-title":"The evolving role of genomic testing in early breast cancer: implications for diagnosis, prognosis, and therapy","volume":"25","author":"Venetis","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.breast.2026.104903_bib22","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"van de Vijver","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104903_bib23","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104903_bib24","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1200\/JCO.2012.46.1558","article-title":"Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy","volume":"31","author":"Dowsett","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104903_bib25","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1038\/bjc.2013.671","article-title":"The EndoPredict score provides prognostic information on late distant metastases in ER+\/HER2- breast cancer patients","volume":"109","author":"Dubsky","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2026.104903_bib26","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1158\/1078-0432.CCR-13-0804","article-title":"Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104903_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-023-01643-2","article-title":"Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial","volume":"25","author":"Zhang","year":"2023","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2026.104903_bib28","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S1470-2045(13)70387-5","article-title":"Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population","volume":"14","author":"Sgroi","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104903_bib29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/1078-0432.CCR-20-2737","article-title":"Breast cancer index predicts extended endocrine benefit to individualize selection of patients with HR+ early-stage breast cancer for 10 years of endocrine therapy","volume":"27","author":"Noordhoek","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104903_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/1177271918789100","article-title":"Development of a novel proteomic risk-classifier for prognostication of patients with early-stage hormone receptor\u2013positive breast cancer","volume":"13","author":"Ramkumar","year":"2018","journal-title":"Biomark Insights"},{"key":"10.1016\/j.breast.2026.104903_bib31","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/cam4.2049","article-title":"Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients","volume":"8","author":"Bakre","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.breast.2026.104903_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2021.05.007","article-title":"The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin","volume":"59","author":"Chandra Doval","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104903_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2022.02.010","article-title":"A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort","volume":"63","author":"Gunda","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104903_bib34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10549-022-06729-7","article-title":"A comparative analysis of recurrence risk predictions in ER+\/HER2\u2212 early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast","volume":"196","author":"Gunda","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104903_bib35","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5443-5","article-title":"Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor positive breast cancer patients","volume":"19","author":"Attuluri","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2026.104903_bib36","first-page":"1013","article-title":"Validation of CanAssist Breast immunohistochemistry biomarkers on an automated platform and its applicability in tissue microarray","volume":"14","author":"Serkad","year":"2021","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.breast.2026.104903_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaf079","article-title":"MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data","volume":"9","author":"Brufsky","year":"2025","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.breast.2026.104903_bib38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-Gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104903_bib39","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jnci\/djj329","article-title":"Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer","volume":"98","author":"Buyse","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2026.104903_bib40","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1001\/jamaoncol.2017.1261","article-title":"Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades","volume":"3","author":"Esserman","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104903_bib41","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.506","article-title":"Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer","volume":"42","author":"Cobain","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104903_bib42","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1200\/JCO.2014.55.6894","article-title":"Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 ris\u2026","volume":"33","author":"Sestak","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104903_bib43","article-title":"Selection of patients with early-stage breast cancer for extended endocrine therapy: a secondary analysis of the IDEAL randomized clinical trial","volume":"7","author":"van\u2019t Veer","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.breast.2026.104903_bib44","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.7150\/jca.24744","article-title":"Gene expression detection assay for cancer clinical use","volume":"9","author":"Narrandes","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.breast.2026.104903_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2026.103136","article-title":"Multigene assays in early breast cancer: current evidence, limits and future directions","volume":"146","author":"Fina","year":"2026","journal-title":"Cancer Treat Rev"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:32:47Z","timestamp":1789612367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626002134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"alternative-id":["S0960977626002134"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104903","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarker-based risk stratification for predicting late recurrence and benefit of extended endocrine therapy: A secondary analysis of the IDEAL trial","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104903"}}